tiprankstipranks
Inspire Medical (DE:2DR)
NYSE:2DR
Germany Market
2DR
Inspire Medical Systems
RESEARCH TOOLSreports

Inspire Medical Systems (2DR) Stock Forecast & Price Target

11 Followers
See the Price Targets and Ratings of:

2DR Analyst Ratings

Hold
12Ratings
Hold
3 Buy
8 Hold
1 Sell
Based on 12 analysts giving stock ratings to
Inspire
Medical Systems
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

2DR Stock 12 Month Forecast

Average Price Target

€45.47
▼(-4.47% Downside)
Based on 12 Wall Street analysts offering 12 month price targets for Inspire Medical Systems in the last 3 months. The average price target is €45.47 with a high forecast of €56.41 and a low forecast of €33.84. The average price target represents a -4.47% change from the last price of €47.60.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"32":"€32","54":"€54","76":"€76","98":"€98","120":"€120"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":56.40725675,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€56.41</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":45.47292697999999,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€45.47</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":33.84435405,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€33.84</span>\n  </div></div>","useHTML":true}}],"tickPositions":[32,54,76,98,120],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Sep<br/>2025","6":"Dec<br/>2025","9":"Mar<br/>2026","12":"Jun<br/>2026","25":"Jun<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,35.8,37.38517359615384,38.97034719230769,40.555520788461536,42.14069438461539,43.72586798076923,45.311041576923074,46.896215173076925,48.48138876923077,50.06656236538461,51.65173596153846,53.23690955769231,54.82208315384615,{"y":56.40725675,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,35.8,36.544071306153846,37.28814261230769,38.03221391846154,38.77628522461538,39.52035653076923,40.26442783692307,41.00849914307692,41.75257044923076,42.49664175538461,43.24071306153845,43.9847843676923,44.72885567384614,{"y":45.47292697999999,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,35.8,35.64956569615384,35.49913139230769,35.348697088461535,35.19826278461538,35.047828480769226,34.89739417692307,34.746959873076925,34.59652556923077,34.44609126538462,34.29565696153846,34.14522265769231,33.994788353846154,{"y":33.84435405,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":119.25,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":108.45,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":105.7,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":78.82,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":60.86,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":61.5,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":106.7,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":78.32,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":62.12,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 19, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":53.82,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":42.77,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":45.4,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":35.8,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target€56.41Average Price Target€45.47Lowest Price Target€33.84
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Bank of America Securities Analyst forecast on DE:2DR
Travis Steed
Bank of America Securities
Bank of America Securities
€45.99→€33.84
Sell
-28.90%
Downside
Downgraded
05/22/26
Inspire Medical downgraded to Underperform from Neutral at BofAInspire Medical downgraded to Underperform from Neutral at BofA
Oppenheimer Analyst forecast on DE:2DR
Suraj Kalia
Oppenheimer
Oppenheimer
―
Hold
―
Reiterated
05/07/26
Oppenheimer sees new MAC billing change as fresh headache for Inspire MedicalOppenheimer sees new MAC billing change as fresh headache for Inspire Medical
Piper Sandler Analyst forecast on DE:2DR
Adam Maeder
Piper Sandler
Piper Sandler
€73.76→€47.73
Hold
0.27%
Upside
Downgraded
05/05/26
Inspire Medical downgraded to Neutral from Overweight at Piper SandlerInspire Medical downgraded to Neutral from Overweight at Piper Sandler
Truist Financial Analyst forecast on DE:2DR
Richard Newitter
Truist Financial
Truist Financial
€55.54→€43.39
Hold
-8.84%
Downside
Reiterated
05/05/26
Truist Financial Sticks to Its Hold Rating for Inspire Medical Systems (INSP)
J.P. Morgan Analyst forecast on DE:2DR
Robbie Marcus
J.P. Morgan
J.P. Morgan
€58.14→€46.86
Hold
-1.55%
Downside
Reiterated
05/05/26
Inspire Medical price target lowered to $54 from $67 at JPMorganInspire Medical price target lowered to $54 from $67 at JPMorgan
Mizuho Securities Analyst forecast on DE:2DR
Anthony Petrone
Mizuho Securities
Mizuho Securities
€60.75→€47.73
Buy
0.27%
Upside
Reiterated
05/05/26
Inspire Medical price target lowered to $55 from $70 at MizuhoInspire Medical price target lowered to $55 from $70 at Mizuho
Stifel Nicolaus Analyst forecast on DE:2DR
Jonathan Block
Stifel Nicolaus
Stifel Nicolaus
€60.75→€56.41
Buy
18.50%
Upside
Reiterated
05/05/26
Stifel Nicolaus Reaffirms Their Buy Rating on Inspire Medical Systems (INSP)
Robert W. Baird Analyst forecast on DE:2DR
David Rescott
Robert W. Baird
Robert W. Baird
€54.67→€43.39
Hold
-8.84%
Downside
Reiterated
05/05/26
Inspire Medical price target lowered to $50 from $63 at BairdInspire Medical price target lowered to $50 from $63 at Baird
Wells Fargo Analyst forecast on DE:2DR
Larry Biegelsen
Wells Fargo
Wells Fargo
€60.75→€48.6
Hold
2.09%
Upside
Reiterated
05/05/26
Analysts' Opinions Are Mixed on These Healthcare Stocks: Cabaletta Bio (NASDAQ: CABA), Inspire Medical Systems (NYSE: INSP) and UnitedHealth (NYSE: UNH)
Evercore ISI Analyst forecast on DE:2DR
Daniel Markowitz CFA
Evercore ISI
Evercore ISI
€53.8→€47.73
Buy
0.27%
Upside
Reiterated
05/05/26
Inspire Medical price target lowered to $55 from $62 at Evercore ISIInspire Medical price target lowered to $55 from $62 at Evercore ISI
KeyBanc Analyst forecast on DE:2DR
Brett Fishbin
KeyBanc
KeyBanc
―
Hold
―
Reiterated
05/05/26
Analysts' Opinions Are Mixed on These Healthcare Stocks: Xencor (NASDAQ: XNCR), Inspire Medical Systems (NYSE: INSP) and Amgen (NASDAQ: AMGN)
RBC Capital Analyst forecast on DE:2DR
Shagun Singh Chadha
RBC Capital
RBC Capital
€48.6→€39.05
Hold
-17.96%
Downside
Reiterated
05/04/26
RBC Capital Keeps Their Hold Rating on Inspire Medical Systems (INSP)
Morgan Stanley Analyst forecast on DE:2DR
Patrick Wood
Morgan Stanley
Morgan Stanley
€112.81→€52.07
Hold
9.39%
Upside
Reiterated
02/19/26
Inspire Medical price target lowered to $60 from $130 at Morgan StanleyInspire Medical price target lowered to $60 from $130 at Morgan Stanley
Wolfe Research Analyst forecast on DE:2DR
Michael Polark
Wolfe Research
Wolfe Research
―
Hold
―
Downgraded
02/13/26
Inspire Medical downgraded to Peer Perform from Outperform at Wolfe ResearchInspire Medical downgraded to Peer Perform from Outperform at Wolfe Research
UBS Analyst forecast on DE:2DR
Danielle Antalffy
UBS
UBS
€77.23→€58.14
Hold
22.15%
Upside
Reiterated
02/13/26
Inspire Medical price target lowered to $67 from $89 at UBSInspire Medical price target lowered to $67 from $89 at UBS
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Bank of America Securities Analyst forecast on DE:2DR
Travis Steed
Bank of America Securities
Bank of America Securities
€45.99→€33.84
Sell
-28.90%
Downside
Downgraded
05/22/26
Inspire Medical downgraded to Underperform from Neutral at BofAInspire Medical downgraded to Underperform from Neutral at BofA
Oppenheimer Analyst forecast on DE:2DR
Suraj Kalia
Oppenheimer
Oppenheimer
―
Hold
―
Reiterated
05/07/26
Oppenheimer sees new MAC billing change as fresh headache for Inspire MedicalOppenheimer sees new MAC billing change as fresh headache for Inspire Medical
Piper Sandler Analyst forecast on DE:2DR
Adam Maeder
Piper Sandler
Piper Sandler
€73.76→€47.73
Hold
0.27%
Upside
Downgraded
05/05/26
Inspire Medical downgraded to Neutral from Overweight at Piper SandlerInspire Medical downgraded to Neutral from Overweight at Piper Sandler
Truist Financial Analyst forecast on DE:2DR
Richard Newitter
Truist Financial
Truist Financial
€55.54→€43.39
Hold
-8.84%
Downside
Reiterated
05/05/26
Truist Financial Sticks to Its Hold Rating for Inspire Medical Systems (INSP)
J.P. Morgan Analyst forecast on DE:2DR
Robbie Marcus
J.P. Morgan
J.P. Morgan
€58.14→€46.86
Hold
-1.55%
Downside
Reiterated
05/05/26
Inspire Medical price target lowered to $54 from $67 at JPMorganInspire Medical price target lowered to $54 from $67 at JPMorgan
Mizuho Securities Analyst forecast on DE:2DR
Anthony Petrone
Mizuho Securities
Mizuho Securities
€60.75→€47.73
Buy
0.27%
Upside
Reiterated
05/05/26
Inspire Medical price target lowered to $55 from $70 at MizuhoInspire Medical price target lowered to $55 from $70 at Mizuho
Stifel Nicolaus Analyst forecast on DE:2DR
Jonathan Block
Stifel Nicolaus
Stifel Nicolaus
€60.75→€56.41
Buy
18.50%
Upside
Reiterated
05/05/26
Stifel Nicolaus Reaffirms Their Buy Rating on Inspire Medical Systems (INSP)
Robert W. Baird Analyst forecast on DE:2DR
David Rescott
Robert W. Baird
Robert W. Baird
€54.67→€43.39
Hold
-8.84%
Downside
Reiterated
05/05/26
Inspire Medical price target lowered to $50 from $63 at BairdInspire Medical price target lowered to $50 from $63 at Baird
Wells Fargo Analyst forecast on DE:2DR
Larry Biegelsen
Wells Fargo
Wells Fargo
€60.75→€48.6
Hold
2.09%
Upside
Reiterated
05/05/26
Analysts' Opinions Are Mixed on These Healthcare Stocks: Cabaletta Bio (NASDAQ: CABA), Inspire Medical Systems (NYSE: INSP) and UnitedHealth (NYSE: UNH)
Evercore ISI Analyst forecast on DE:2DR
Daniel Markowitz CFA
Evercore ISI
Evercore ISI
€53.8→€47.73
Buy
0.27%
Upside
Reiterated
05/05/26
Inspire Medical price target lowered to $55 from $62 at Evercore ISIInspire Medical price target lowered to $55 from $62 at Evercore ISI
KeyBanc Analyst forecast on DE:2DR
Brett Fishbin
KeyBanc
KeyBanc
―
Hold
―
Reiterated
05/05/26
Analysts' Opinions Are Mixed on These Healthcare Stocks: Xencor (NASDAQ: XNCR), Inspire Medical Systems (NYSE: INSP) and Amgen (NASDAQ: AMGN)
RBC Capital Analyst forecast on DE:2DR
Shagun Singh Chadha
RBC Capital
RBC Capital
€48.6→€39.05
Hold
-17.96%
Downside
Reiterated
05/04/26
RBC Capital Keeps Their Hold Rating on Inspire Medical Systems (INSP)
Morgan Stanley Analyst forecast on DE:2DR
Patrick Wood
Morgan Stanley
Morgan Stanley
€112.81→€52.07
Hold
9.39%
Upside
Reiterated
02/19/26
Inspire Medical price target lowered to $60 from $130 at Morgan StanleyInspire Medical price target lowered to $60 from $130 at Morgan Stanley
Wolfe Research Analyst forecast on DE:2DR
Michael Polark
Wolfe Research
Wolfe Research
―
Hold
―
Downgraded
02/13/26
Inspire Medical downgraded to Peer Perform from Outperform at Wolfe ResearchInspire Medical downgraded to Peer Perform from Outperform at Wolfe Research
UBS Analyst forecast on DE:2DR
Danielle Antalffy
UBS
UBS
€77.23→€58.14
Hold
22.15%
Upside
Reiterated
02/13/26
Inspire Medical price target lowered to $67 from $89 at UBSInspire Medical price target lowered to $67 from $89 at UBS
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
TRAXFirst Tracks Biotherapeutics Inc
EVMNEvommune, Inc.
MPLTMapLight Therapeutics, Inc.
MAZEMaze Therapeutics, Inc.
AAPGAscentage Pharma Group International Unsponsored ADR
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Inspire Medical Systems

3 Months
Frank TakkinenLake Street
Success Rate
14/23 ratings generated profit
61%
Average Return
+9.11%
Copying Frank Takkinen's trades and holding each position for 3 Months would result in 60.87% of your transactions generating a profit, with an average return of +9.11% per trade.
1 Year
Jonathan BlockStifel Nicolaus
Success Rate
11/22 ratings generated profit
50%
Average Return
+23.04%
Copying Jonathan Block's trades and holding each position for 1 Year would result in 50.00% of your transactions generating a profit, with an average return of +23.04% per trade.
2 Years
Jonathan BlockStifel Nicolaus
Success Rate
11/22 ratings generated profit
50%
Average Return
+51.15%
Copying Jonathan Block's trades and holding each position for 2 Years would result in 50.00% of your transactions generating a profit, with an average return of +51.15% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

2DR Analyst Recommendation Trends

Rating
Feb 26
Mar 26
Apr 26
May 26
Jun 26
Strong Buy
12
7
2
1
1
Buy
12
6
7
8
6
Hold
19
16
14
14
13
Sell
0
0
0
1
1
Strong Sell
0
0
0
0
0
total
43
29
23
24
21
In the current month, 2DR has received 7 Buy Ratings, 13 Hold Ratings, and 1 Sell Ratings. 2DR average Analyst price target in the past 3 months is 45.47.
Each month's total comprises the sum of three months' worth of ratings.

2DR Financial Forecast

2DR Earnings Forecast

Next quarter’s earnings estimate for 2DR is -€0.21 with a range of -€0.32 to -€0.13. The previous quarter’s EPS was €0.09. 2DR beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year 2DR has Performed in-line its overall industry.
Next quarter’s earnings estimate for 2DR is -€0.21 with a range of -€0.32 to -€0.13. The previous quarter’s EPS was €0.09. 2DR beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year 2DR has Performed in-line its overall industry.

2DR Sales Forecast

Next quarter’s sales forecast for 2DR is €165.64M with a range of €154.52M to €168.18M. The previous quarter’s sales results were €174.65M. 2DR beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year 2DR has Performed in-line its overall industry.
Next quarter’s sales forecast for 2DR is €165.64M with a range of €154.52M to €168.18M. The previous quarter’s sales results were €174.65M. 2DR beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year 2DR has Performed in-line its overall industry.

2DR Stock Forecast FAQ

What is DE:2DR’s average 12-month price target, according to analysts?
Based on analyst ratings, Inspire Medical’s 12-month average price target is 45.47.
    What is DE:2DR’s upside potential, based on the analysts’ average price target?
    Currently there's no upside potential for DE:2DR, based on the analysts’ average price target.
    Can I see which stocks the top-ranking analysts are rating?
    Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
      How can I follow the stock ratings of top Wall Street analysts?
      Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
        Is Inspire Medical a Buy, Sell or Hold?
        Inspire Medical has a consensus rating of Hold, which is based on 3 buy ratings, 8 hold ratings and 1 sell ratings.
          What is Inspire Medical’s share price target?
          The average share price target for Inspire Medical is 45.47. This is based on 12 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
          The highest analyst share price target is €56.41 ,and the lowest forecast is €33.84. The average share price target represents -4.47% Decrease from the current price of €47.6.
            What do analysts say about Inspire Medical?
            Inspire Medical’s analyst rating consensus is a Hold. This is based on the ratings of 12 Wall Streets Analysts.
              How can I buy shares of Inspire Medical?
              To buy shares of DE:2DR, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.